Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites

Regulatory Toxicology and Pharmacology

Volumn 46, Issue 1, 2006, Pages 63-83

  Eric Hack, C ^a   Chiu, Weihsueh A ^b   Jay Zhao, Q ^a   Clewell, Harvey J ^c  

^a Toxicology Excellence for Risk Assessment   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c ENVIRON Health Sciences Institute   (United States)

Author keywords

Bayesian analysis; Dosimetry; PBPK; Pharmacokinetics; TCE; Trichloroethylene

Indexed keywords

CHLORAL HYDRATE; DICHLOROACETIC ACID; THIOL DERIVATIVE; TRICHLOROACETIC ACID; TRICHLOROETHANOL; TRICHLOROETHYLENE;

ANIMAL TISSUE; ARTICLE; BAYES THEOREM; CANCER RISK; CONCENTRATION (PARAMETERS); HUMAN; HUMAN TISSUE; KINETICS; METABOLITE; MOUSE; NONHUMAN; PHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

ANIMALS; BAYES THEOREM; CHLORAL HYDRATE; DICHLOROACETATE; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHYLENE CHLOROHYDRIN; HUMANS; KINETICS; MARKOV CHAINS; MICE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; RATS; SULFHYDRYL COMPOUNDS; TRICHLOROACETIC ACID; TRICHLOROETHYLENE;

ANIMALIA;

EID: 33747890699     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2006.05.012     Document Type: Article

References (44)

1. Abbas R., and Fisher J.W. A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. Toxicol. Appl. Pharmacol. 147 (1997) 15-30
2. Allen B.D., and Fisher J.W. Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans. Risk Anal. 13 (1993) 71-86
3. Andersen M.E., Clewell H.J., Gargas M.L., Smith F.A., and Reitz R.H. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87 (1987) 185-205
4. Astrand P., and Rodahl K. Textbook of Work Physiology (1970), McGraw-Hill, New York, NY
5. Bernauer U., Birner G., Dekant W., and Henschler D. Biotransformation of trichloroethylene: dose-dependent excretion of 2,2,2-trichlor-metabolites and mercapturic acids in rats and humans after inhalation. Arch. Toxicol. 70 (1996) 338-346
6. Bernillon P., and Bois F. Statistical issues in toxicokinetic modeling: a bayesian perspective. Environ. Health Perspect. 108 (2000) 883-893
7. Bois F. Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. Environ. Health Perspect. 108 (2000) 307-316
8. Bois F. Statistical analysis of Fisher PBPK model of trichloroethylene kinetics. Environ. Health Perspect. 108 (2000) 275-282
9. Bois, F., Maszle, D., Revzan, K., Tillier, S., Yuan, Z., 2005. MCSIM: logiciel de simulation [MCSim Simulation Package]. Experimental Toxicology Unit, INERIS, Verneuil-en-Halatte, France. http://toxi.ineris.fr/en/activites/toxicologie_quantitative/mcsim/mcsim.php.
10. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., and Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13 (1997) 407-484
11. Carlin B.P., and Louis T.A. Bayes and Empirical Bayes Methods for Data Analysis (2000), Chapman & Hall, CRC Press Inc., Boca Raton, FL
12. Clewell H.J., Gentry P.R., Allen B.C., Covington T.R., and Gearhart J.M. Development of a physiologically based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ. Health Perspect. 108 (2000) 283-305
13. Clewell H.J., Andersen M.E., and Barton H.A. A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. Environ. Health Perspect. 110 (2002) 85-93
14. Covington, T.R., Clewell, H.J., Fisher, J.W., 2006. Development of a physiologically-based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Human Effectiveness Directorate, Biosciences and Protection Division, Wright-Patterson AFB, OH, AFRL-HE-WP-TR-2006-0049. Available online: stinet.dtic.mil.
15. Fisher J.W. Physiologically based pharmacokinetic models for trichloroethylene and its oxidative metabolites. Environ. Health Perspect. 108 (2000) 265-273
16. Fisher J.W., Gargas M.L., Allen B.C., and Andersen M.E. Physiologically based pharmacokinetic modeling with trichloroethylene and its metabolite, trichloroacetic acid, in the rat and mouse. Toxicol. Appl. Pharmacol. 109 (1991) 183-195
17. Fisher J.W., Mahle D.A., and Abbas R. A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. Toxicol. Appl. Pharmacol. 152 (1998) 339-359
18. Gelman A. Inference and monitoring convergence. In: Gilks W.R., Richardson S., and Spiegelhalter D.J. (Eds). Markov Chain Monte Carlo in Practice (1996), Chapman & Hall, CRC Press Inc., Boca Raton, FL 131-143
19. Gelman A., Bois F., and Jiang J. Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J. Am. Stat. Assoc. 91 (1996) 1400-1412
20. Gilks W.R., Richardson S., and Spiegelhalter D.J. Markov Chain Monte Carlo in Practice (1996), Chapman & Hall, CRC Press Inc., Boca Raton, FL
21. Greenberg M.S., Burton G.A., and Fisher J.W. Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F1 mice. Toxicol. Appl. Pharmacol. 154 (1999) 264-278
22. Hack C.E. Bayesian analysis of physiologically-based toxicokinetic and toxicodynamic models. Toxicology 221 (2006) 241-248
23. ICRP (International Commision on Radiological Protection), 1975. Report of the Task Group on Reference Man. Pergamon Press, Oxford.
24. Jepson G.W., Hoover D.K., Black R.K., McCafferty J.D., Mahle D.A., and Gearhart J.M. A partition coefficient determination method for nonvolatile chemicals in biological tissues. Fundam. Appl. Toxicol. 22 (1994) 519-524
25. Jonsson F., Bois F., and Johanson G. Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology 157 (2001) 177-193
26. Jonsson F., Bois F., and Johanson G. Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise. Toxicol. Sci. 59 (2001) 209-218
27. Jonsson F., and Johanson G. Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology 157 (2001) 177-193
28. Jonsson F., and Johanson G. Physiologically based modeling of the inhalation kinetics of styrene in humans using a bayesian population approach. Toxicol. Appl. Pharmacol. 179 (2002) 35-49
29. Lapare S., Tardif R., and Brodeur J. Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air. II. 1,1,1-Trichloroethane and trichloroethylene. Int. Arch. Occup. Environ. Health 67 6 (1995) 375-394
30. Larson J.L., and Bull R.J. Species differences in the metabolism of trichloroethylene to the carcinogenic metabolites trichloroacetate and dichloroacetate. Toxicol. Appl. Pharmacol. 115 (1992) 278-285
31. Lipscomb J.L., Fisher J.W., Confer P.D., and Byczkowski J.Z. In vitro to in vivo extrapolation of trichloroethylene metabolism in humans. Toxicol. Appl. Pharmacol. 152 (1998) 376-387
32. Lumpkin M.H., Dallas C.E., Bruckner J.V., and Fisher J.W. Physiologically based pharmacokinetic modeling of species-specific effects of plasma binding of trichloroacetic acid from trichloroethylene in mice, rats, and humans. Toxicologist 72 (2003) 867
33. Marino D.J., Clewell III H.J., Gentry P.R., Covington T.R., Hack C.E., David R.M., and Morgott D.A. Revised assessment of cancer risk to dichloromethane: Part I Bayesian PBPK and dose-response modeling in mice. Regul. Toxicol. Pharmacol. 45 (2006) 44-54
34. Monster A., Boersma G., and Duba W. Kinetics of trichloroethylene in repeated exposure of volunteers. Int. Arch. Occup. Environ. Health. 42 (1979) 283-292
35. Muller G., Spassovski M., and Henschler D. Trichloroethylene exposure and trichloroethylene metabolites in urine and blood. Arch. Toxikol. 29 (1972) 335-340
36. Muller G., Spassowski M., and Henschler D. Metabolism of trichloroethylene in man. II. Pharmacokinetics of metabolites. Arch. Toxikol. 32 (1974) 283-295
37. Muller G., Spassowski M., and Henschler D. Metabolism of trichloroethylene in man. III. Interaction of trichloroethylene and ethanol. Arch. Toxikol. 33 (1975) 173-189
38. Prout M.S., Provan W.M., and Green T. Species differences in response to trichloroethylene. Toxicol. Appl. Pharmacol. 79 (1985) 389-400
39. Stewart R., Dodd H.C., Gay H.H., and Erley D.S. Experimental human exposure to trichloroethylene. Arch. Environ. Health 20 (1970) 64-71
40. Triebig G., Essing H.G., Schaller K.H., and Valentin H. Biochemical and psychological examinations of trichloroethylene exposed volunteers. Zentralbl. Bakteriol. 163 5-6 (1976) 383-416
41. Templin M.V., Parker J.C., and Bull R.J. Relative formation of dichloroacetate and trichloroacetate from trichloroethylene in male B6C3F1 mice. Toxicol. Appl. Pharmacol. 123 (1993) 1-8
42. Templin M.V., Stevens D.K., Stenner R.D., Bonate P.L., Tuman D., and Bull R.J. Factors affecting species differences in the kinetics of metabolites of trichloroethylene. J. Toxicol. Environ. Health 44 (1995) 435-447
43. US EPA (US Environmental Protection Agency), 1988. Reference physiological parameters in pharmacokinetic modeling. Office of Research and Development, Washington, DC.
44. US EPA (US Environmental Protection Agency), 2001. Trichloroethylene health risk assessment: Synthesis and characterization (External Review Draft). Office of Research and Development, National Center for Environmental Assessment, Washington, DC, EPA/600/P-01/002A.